Design and Synthesis of Peptidomimetic Severe Acute Respiratory Syndrome Chymotrypsin-like Protease Inhibitors
Journal of Medicinal Chemistry2005Vol. 48(22), pp. 6767–6771
Citations Over TimeTop 10% of 2005 papers
Arun K. Ghosh, Kai Xi, Kiira Ratia, Bernard D. Santarsiero, Wentao Fu, Brian H. Harcourt, Paul A. Rota, Susan C. Baker, Michael E. Johnson, Andrew D. Mesecar
Abstract
Design, synthesis, and biological evaluation of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease (SARS-3CLpro) inhibitors for severe acute respiratory syndrome coronavirus (SARS-CoV) are described. These inhibitors exhibited antiviral activity against SARS-CoV in infected cells in the micromolar range. An X-ray crystal structure of our lead inhibitor (4) bound to SARS-3CLpro provided important drug-design templates for the design of small-molecule inhibitors.
Related Papers
- → The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate(2022)25 cited
- → Molecular Tongs Containing Amino Acid Mimetic Fragments: New Inhibitors of Wild-Type and Mutated HIV-1 Protease Dimerization(2006)36 cited
- → The radioprotective potential of the Bowman–Birk protease inhibitor is independent of its secondary structure(1998)20 cited
- → Protease Inhibitors(1974)36 cited
- → The effect of variation within inhibitory domains on the activity of pea protease inhibitors from the Bowman?Birk class(2004)1 cited